1241920-02-4

Upstream product

• 67-56-1 methanol 
• 195609-18-8 2-(2-fluoro-5-nitrophenyl)acetic acid 

Downstream Products

• 1241920-04-6 methyl 2-(2-fluoro-5-nitrophenyl)-4-methyl-4-pentenoate 
• 1241920-03-5 methyl 2-(2-fluoro-5-nitrophenyl)-4-pentenoate 
• 1338928-39-4 methyl 2-(2-(4-methoxyphenoxy)-5-nitrophenyl)acetate 
• 1338928-70-3 methyl 2-(2-(3-methoxyphenoxy)-5-nitrophenyl)acetate 
• 1338928-71-4 methyl 2-(5-amino-2-(3-methoxyphenoxy)phenyl)acetate 
• 1338928-72-5 methyl 2-(5-bromo-2-(3-methoxyphenoxy)phenyl)acetate 
• 1338928-73-6 2-(5-bromo-2-(3-methoxyphenoxy)phenyl)acetic acid 
• 1338928-40-7 methyl 2-(5-amino-2-(4-methoxyphenoxy)phenyl)acetate 
• 1338928-41-8 methyl 2-(5-bromo-2-(4-methoxyphenoxy)phenyl)acetate 
• 1338928-42-9 2-(5-bromo-2-(4-methoxyphenoxy)phenyl)acetic acid 
• 1616596-25-8 [2-fluoro-5-(1H-tetrazol-1-yl)phenyl]acetic acid 
• 1616596-26-9 methyl [2-fluoro-5-(1H-tetrazol-1-yl)phenyl]acetate 
• 1338367-30-8 methyl 2-(5-amino-2-fluorophenyl)acetate 

Relevant academic research and scientific papers

Selective sodium channel regulator as well as preparation and application thereof

The invention provides a compound serving as a selective sodium channel regulator and a synthesis and use method, and particularly provides a compound shown as a formula (I), a preparation method of the compound and application of the compound serving as the selective sodium channel regulator. The compounds exhibit excellent activity as a regulator of sodium channels.

SUBSTITUTED PYRIMIDINES AND METHODS OF USE

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

MODULATORS OF POTASSIUM ION AND TRPV1 CHANNELS AND USES THEREOF

Novel compounds usable in modulating an activity or function of a voltage-dependent potassium channel and/or of TRPV1 are provided. The compounds are represented by Formula I as described and defined in the specification.

RORGAMMA MODULATORS AND USES THEREOF

The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton’ s tyrosine kinase (Btk), and for treating disorders mediated thereby.

FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kirl.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.